Hosted on MSN
Oppenheimer Initiates Coverage of Atai Life Sciences N.V. (ATAI) with Outperform Recommendation
Fintel reports that on July 29, 2025, Oppenheimer initiated coverage of Atai Life Sciences N.V. (NasdaqGM:ATAI) with a Outperform recommendation. Analyst Price Forecast Suggests 201.20% Upside As of ...
• Apeiron and other key shareholders enter into voluntary lock-up agreements • This voluntary lock-up extends trading restrictions by 24 months for Apeiron and 12 months for other investors • ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
NEW YORK and BERLIN - atai Life Sciences (NASDAQ:ATAI), a biopharmaceutical company focused on mental health treatments with a market capitalization of $272 million, announced significant changes to ...
ATAI Life Sciences N.V. (NASDAQ: ATAI), a biopharmaceutical company, has entered into a significant amendment to its existing loan agreement, securing an additional $5 million in financing and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results